Caneschi S, Bonaventi C, Finzi F, Tito P
Minerva Med. 1985 Oct 20;76(40):1883-94.
A sample of 29 patients suffering from ischaemic cerebrovascular disorders was examined. Of these, 15 were treated with Ditazol (1200 mg/day in three administrations) and 14 with ASA (1 g a day in 2 administration). These patients were evaluated using serial Born and Cross tests to check ADP, Adrenaline and Collagen-induced platelet aggregation. The clinical follow-up lasted 22-34 months. As part of the laboratory evaluation, this sample was also compared with a group of 34 healthy volunteers. Ditazol was found to be an inhibitor of ADP, Adrenaline and Collagen-induced platelet aggregation: this effect constitutes clinical protection against recurrence of the complaint. Recurrence was 13.3% with Ditazol treated patients and 35.7% with ASA.
对29例缺血性脑血管疾病患者进行了检查。其中，15例接受双嘧达莫治疗（每日1200毫克，分三次给药），14例接受阿司匹林治疗（每日1克，分两次给药）。使用连续的博恩和克罗斯试验对这些患者进行评估，以检查二磷酸腺苷（ADP）、肾上腺素和胶原诱导的血小板聚集情况。临床随访持续了22至34个月。作为实验室评估的一部分，该样本还与一组34名健康志愿者进行了比较。发现双嘧达莫是ADP、肾上腺素和胶原诱导的血小板聚集的抑制剂：这种作用构成了对该疾病复发的临床保护。接受双嘧达莫治疗的患者复发率为13.3%，接受阿司匹林治疗的患者复发率为35.7%。
